Refine by
Post Injection Operation Articles & Analysis
92 news found
In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its significance, and the method of ...
HIFU ultrasound machine is a non-surgical SMAS facelift procedure that uses non-invasive high energy focused ultrasound (HIFU) to stimulate the skin's natural regenerative and repair response, tightening the subcutaneous fascia layer and allowing the skin to regenerate collagen on its own, remodelling the elastic fibres and forming a strong elastic support network, thus achieving a strong ...
Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label. ...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from ...
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA-cleared, clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis and a patented intuitive display of contextual patient data for more efficient, actionable clinical decisions. As part of the recently ...
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. ...
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
Fractional laser is a commonly used instrument in clinical beauty medicine. In addition to treating acne scars, burn scars, and trauma scars, it also has a good effect on facial rejuvenation, freckle removal, skin shrinking, and stretch marks. Bvlaser is a CO2 fractional laser machine factory supplier, we have best fractional laser machine for sale. What is fractional laser Fractional laser ...
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics ...
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced that the Company’s management will be participating in the 2022 Jeffries Innovation inMental Health Summit. ...
Results show a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in pre-surgical patients Top line results met primary endpoint and showed nasal photodisinfection eliminated or significantly decreased Staphylococcus aureus ( aureus) in 92% of carriers treated per protocol (P<0.001). All of the 319 ...
Aatru Medical, LLC ("Aatru") today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...
Empirical Spine, Inc., a company developing advanced solutions for the surgical treatment of spinal disorders, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its LimiFlex™ Paraspinous Tension Band. In doing so, the FDA has determined that LimiFlex™ holds the potential to offer significant advantages over ...
With the continuous development of modern medical beauty technology, people's increasingly diversified needs for beauty are also being further met. Especially in recent years, all kinds of medical beauty equipment and technologies have blossomed, and the demand for facial rejuvenation has exploded. The choice of technology will inevitably make it difficult for consumers. Want to have smooth and ...
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...
Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s nasal photodisinfection technology eradicates pathogens – specifically Staphylococcus aureus – in the nose. The single-center, BENEFIT-aPDT open-label study is being carried out at HCA Healthcare’s ...
Combining capabilities to develop breakthrough technologies for transforming surgery. Hospitals and Surgery Centers face many challenges in surgery as they work to recover from COVID. Directors of Perioperative Services, Surgeons, OR Staff and OR managers are facing high levels of stress with maintaining quality patient care, increasing surgical case volume from backlogs, while at the same time ...
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023 Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that ...
ByRobocath